Lung Transplant Program at Baylor St. Luke's Medical Center

The Lung Transplant Program at Baylor St. Luke's has been performing successful lung and heart-lung transplants since the 1990s. Lung transplants may be recommended for patients with severe end-stage lung disease caused by emphysema, cystic fibrosis, chronic diseases such as sarcoidosis, idiopathic pulmonary fibrosis (permanent scarring and thickening of lung tissue), pulmonary hypertension, or congenital diseases. After a thorough evaluation, recommendations may include either single lung transplant, double lung transplant, or heart and lung transplant.

Speak with a Baylor St. Luke's Lung Transplant Representative at (832) 355-2285.

Breathing Lung Transplant Program

The Breathing Lung Transplant Program describes a mode of transplantation where the donor lung is kept breathing and warm, with blood pumping through it from the time of the donor procedure all the way to the recipient implant. This utilizes a technology known as ex-vivo lung perfusion (EVLP), which has several components that allow the lung to remain in a physiologic state throughout transportation.

The organ care system (OCS) is the only portable EVLP system in the world and the only EVLP system that has undergone a positive FDA panel review in the United States as well as two rigorous international clinical


trials. Interim trial results suggest that donor lungs in ideal condition transported in the OCS according to protocol had a 50-percent reduction in the incidence of graft dysfunction compared to those transported in standard ice coolers.

Because an estimated 5-10 percent of donor lung offers meet “standard or ideal conditions,” the EXPAND I trial was conducted to see the effect of the OCS on lungs that were outside of the ideal scenario. The EXPAND I interim results suggested 88 percent utilization of such lungs. That means double the number of potentially transplantable organs and a reduction in the time patients spend on the waitlist. For questions regarding the OCS, please call 832-355-2285.

Baylor St. Luke’s Medical Center is the first site in the nation to begin the EXPAND II clinical trial and the first site in Texas to utilize the OCS lung platform. In the EXPAND II trial, we will compare transplantation using the OCS in extended criteria donors to the outcomes of standard ice transplantation in standard donors. For more information on this trial, please contact us at 832-355-2285.

Featured Updates

New Technology Gives Patients With COPD More Treatment Options

NOV 20, 2019

Chronic lower respiratory disease, or CLRD, is the fourth leading cause of death in the United States. Chronic obstructive pulmonary disorder, or COPD, is a form of CLRD. And while no cure exists for COPD, there are a number of effective treatments t...

Read More Additional information about New Technology Gives Patients With COPD More Treatment Options | St. Luke's Health

HIPEC: A 3-in-1 Approach to Treating Cancer

NOV 01, 2019

If you’ve ever dropped a glass on the floor, you may have responded by sweeping up the largest shards and then vacuuming to get the tiny pieces that remained. This is the general idea behind combining cytoreductive surgery and the HIPEC procedure for...

Read More Additional information about HIPEC: A 3-in-1 Approach To Treating Cancer | St. Luke's Health

Find a Doctor

Looking for a doctor? Perform a quick search by name or browse by specialty.

Contact Us

Speak with a Baylor St. Luke's Transplant Representative

Toll Free

International Patients